Publications by authors named "W J Moran"
Hypervalent iodine-mediated cyclization of bishomoallylamides to prolinols.
Beilstein J Org Chem
September 2024
A change in mechanism was observed in the hypervalent iodine-mediated cyclization of -alkenylamides when the carbon chain between the alkene and the amide increased from two to three atoms. In the latter case, cyclization at the amide nitrogen to form the pyrrolidine ring was favored over cyclization at the amide oxygen. A DFT study was undertaken to rationalize the change in mechanism of this cyclization process.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate the effectiveness of a patient navigator in a patient-centered medical home (PCMH) for managing uncontrolled hypertension and diabetes mellitus (DM) among primary care patients.
- Implementation of this navigator led to significant improvements, with a roughly 40% reduction in uncontrolled systolic blood pressure (SBP) and a 30% reduction in uncontrolled hemoglobin A1c (HbA1c) levels after 12 months.
- The findings suggest that having a dedicated patient navigator can greatly enhance blood pressure and glycemic control without differences based on race or poverty levels.
Background: We examined the association of objective measures of cardiometabolic risk with progression to a high-risk for advanced fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) at initially low- and indeterminate-risk for advanced fibrosis.
Methods: We performed a retrospective cohort study of primary care patients with MASLD between 2012 and 2021. We evaluated patients with MASLD and low- or indeterminate-risk Fibrosis-4 Index (FIB-4) scores and followed them until the outcome of a high-risk FIB-4 (≥2.
Glucagon-like peptide-1 receptor agonist (GLP-1a) medications have been shown in randomized controlled trials (RCTs) to have consistent and impressive effectiveness in lowering hemoglobin A1c (HbA1c) and weight, but limited data exist on the efficacy of GLP-1a medications in clinical practice. We studied the association between GLP-1a therapy and changes in weight and HbA1c in a real-world patient population. In this retrospective cohort study of patients seen in a primary care clinic between 2012 and 2021, we examined the change in weight and HbA1c over 12 months in a cohort of patients with at least one prescription for a GLP-1a.
View Article and Find Full Text PDFObjective: We aimed to determine the association of statins with progression to a high risk for advanced fibrosis in primary care patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
Design: This retrospective cohort study of electronic health record data included patients with MASLD and an initial low or indeterminate risk for advanced fibrosis, determined by Fibrosis-4 Index (FIB-4) score (<2.67).